{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-095439","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.403686+00:00","generated_at":"2026-05-31T10:17:39.529260+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aspira Women's Health Q2 revenue $2.4M; cuts FY cash guidance to $13-14.5M","bullets":["Q2 product revenue $2.4M vs $2.5M YoY; OvaSuite volume 6,471 units (+3%).","Gross margin 59% vs 62% YoY; operating cash used $3.7M in Q2.","Cash at June 30: $1.0M; subsequent raises of $4.0M boosted pro forma cash to $5.0M.","Full-year 2024 cash guidance lowered to $13-14.5M from $15-18M.","OvaWatch volume grew 48% YoY; John Kallassy appointed interim CFO effective Aug 15."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-095439","json":"https://secwatch.observer/filing/0000950170-24-095439.json","markdown":"https://secwatch.observer/filing/0000950170-24-095439.md","text":"https://secwatch.observer/filing/0000950170-24-095439.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000095017024095439/0000950170-24-095439-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000095017024095439/awh-20240812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:17:39.529260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}